These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 24099328)
41. Classification of stimuli-responsive polymers as anticancer drug delivery systems. Taghizadeh B; Taranejoo S; Monemian SA; Salehi Moghaddam Z; Daliri K; Derakhshankhah H; Derakhshani Z Drug Deliv; 2015 Feb; 22(2):145-55. PubMed ID: 24547737 [TBL] [Abstract][Full Text] [Related]
42. Implantable microchip: the futuristic controlled drug delivery system. Sutradhar KB; Sumi CD Drug Deliv; 2016; 23(1):1-11. PubMed ID: 24758139 [TBL] [Abstract][Full Text] [Related]
43. Recent trends of nanomedicinal approaches in clinics. Dilnawaz F; Acharya S; Sahoo SK Int J Pharm; 2018 Mar; 538(1-2):263-278. PubMed ID: 29339248 [TBL] [Abstract][Full Text] [Related]
44. Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery. Khakar PS Curr Top Med Chem; 2010; 10(1):116-26. PubMed ID: 19929825 [TBL] [Abstract][Full Text] [Related]
45. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Sharma A; Madhunapantula SV; Robertson GP Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):47-69. PubMed ID: 22097965 [TBL] [Abstract][Full Text] [Related]
47. The role of multiscale computational approaches for rational design of conventional and nanoparticle oral drug delivery systems. Haddish-Berhane N; Rickus JL; Haghighi K Int J Nanomedicine; 2007; 2(3):315-31. PubMed ID: 18019831 [TBL] [Abstract][Full Text] [Related]
48. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Masimirembwa CM; Bredberg U; Andersson TB Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837 [TBL] [Abstract][Full Text] [Related]
49. Absorption, distribution, metabolism, and excretion of nanocarriers in vivo and their influences. Zhang A; Meng K; Liu Y; Pan Y; Qu W; Chen D; Xie S Adv Colloid Interface Sci; 2020 Oct; 284():102261. PubMed ID: 32942181 [TBL] [Abstract][Full Text] [Related]
50. Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology. Mukherjee B; Dutta L; Mondal L; Dey NS; Chakraborty S; Maji R; Shaw TK Curr Pharm Des; 2015; 21(36):5172-86. PubMed ID: 26412361 [TBL] [Abstract][Full Text] [Related]
51. BCS class IV drugs: Highly notorious candidates for formulation development. Ghadi R; Dand N J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572 [TBL] [Abstract][Full Text] [Related]
52. The dangers of generalization in nanotechnology. Florence AT Drug Discov Today; 2004 Jan; 9(2):60-1. PubMed ID: 15025067 [No Abstract] [Full Text] [Related]
53. Recent progress in dendrimer-based nanocarriers. Bai S; Thomas C; Rawat A; Ahsan F Crit Rev Ther Drug Carrier Syst; 2006; 23(6):437-95. PubMed ID: 17425500 [TBL] [Abstract][Full Text] [Related]
54. Seeing is believing--visualizing drug delivery in vitro and in vivo. Swartz H Adv Drug Deliv Rev; 2005 Jun; 57(8):1085-6. PubMed ID: 15935867 [TBL] [Abstract][Full Text] [Related]
55. Nano-based drug delivery system enhances the oral absorption of lipophilic drugs with extensive presystemic metabolism. Zhang Z; Gao F; Jiang S; Ma L; Li Y Curr Drug Metab; 2012 Oct; 13(8):1110-8. PubMed ID: 22380010 [TBL] [Abstract][Full Text] [Related]
56. Computer-aided Drug Design and Drug Pharmacokinetic Prediction: A Mini-review. Tabeshpour J; Sahebkar A; Zirak MR; Zeinali M; Hashemzaei M; Rakhshani S; Rakhshani S Curr Pharm Des; 2018; 24(26):3014-3019. PubMed ID: 30179125 [TBL] [Abstract][Full Text] [Related]
57. Nanosize drug delivery system. Mukherjee B Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648 [TBL] [Abstract][Full Text] [Related]
58. Role of nanotechnology in developing new therapies for diseases of the nervous system. Jain KK Nanomedicine (Lond); 2006 Jun; 1(1):9-12. PubMed ID: 17716203 [No Abstract] [Full Text] [Related]
59. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. Narang AS; Chang RK; Hussain MA J Pharm Sci; 2013 Nov; 102(11):3867-82. PubMed ID: 24037829 [TBL] [Abstract][Full Text] [Related]
60. Unique benefits of nanotechnology to drug delivery and diagnostics. McNeil SE Methods Mol Biol; 2011; 697():3-8. PubMed ID: 21116949 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]